Alpha 2.0
Login Register
» Authors » Lisette Connell

Lisette Connell

Explore the profile of Lisette Connell including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 132
Followers 0
Related Specialty
Psychiatry
Top 10 Co-Authors
Trino Baptista
Edgardo Carrizo
Ignacio Sandia
Ana Serrano
Enma Araujo de Baptista
Erika Fernandez
Virginia Fernandez
Nairy Rangel
Mercedes Servigna
Euderruh Uzcategui
Published In
Schizophr Res
Aust N Z J Psychiatry
Affiliations
Soon will be listed here.
Recent Articles
1.
Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics
Baptista T, Carrizo E, Fernandez E, Connell L, Servigna M, Parra A, et al.
Schizophr Res . 2015 Jun; 166(1-3):207-11. PMID: 26032569
Background: Constipation occurs in 25-60% of the subjects during administration of the antipsychotic drug (AP) clozapine (CLZ). Methods: We used a colonic transit diagnostic test that quantifies in a single...
2.
Safety of long-term clozapine administration. Frequency of cardiomyopathy and hyponatraemia: two cross-sectional, naturalistic studies
Serrano A, Rangel N, Carrizo E, Uzcategui E, Sandia I, Zabala A, et al.
Aust N Z J Psychiatry . 2013 Aug; 48(2):183-92. PMID: 23985160
Background: The antipsychotic drug (APD) clozapine (CLZ) is under-prescribed because of concerns about its safety. We evaluated in separate protocols the frequency of cardiomyopathy and hyponatraemia, which are adverse drug...
3.
Pro12Ala polymorphism of the PPAR-γ2 gene, metabolic syndrome and response to metformin in clozapine-treated patients
Fernandez E, Carrizo E, Connell L, Baptista T
Schizophr Res . 2012 Mar; 137(1-3):262-3. PMID: 22377103
No abstract available.
4.
The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela
Baptista T, Serrano A, Uzcategui E, ElFakih Y, Rangel N, Carrizo E, et al.
Schizophr Res . 2010 Nov; 126(1-3):93-102. PMID: 21071179
Background: Few studies on the association between atypical antipsychotic drug (AAP) administration and metabolic dysfunction have concurrently evaluated the general population (GP), other psychotropic drug treatments and drug-free psychiatric patients....
5.
Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin
Fernandez E, Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, et al.
Schizophr Res . 2010 Jul; 121(1-3):213-7. PMID: 20591628
Background: The role of leptin in atypical antipsychotic-induced metabolic dysfunction was explored by assessing the anthropometric and metabolic profile and the response to metformin (MET) of clozapine- (CLZ) treated schizophrenia...
6.
Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study
Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, Mogollon J, et al.
Schizophr Res . 2009 Jun; 113(1):19-26. PMID: 19515536
Background: Clozapine is the most effective agent in treatment-resistant schizophrenia. However, it is frequently associated with excessive body weight (BW) gain, type 2 diabetes mellitus and hyperlipidemia. The antidiabetic metformin...
7.
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial
Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcategui E, et al.
Schizophr Res . 2007 May; 93(1-3):99-108. PMID: 17490862
Background: Excessive body weight gain (BWG) is a clinically relevant side effect of olanzapine administration. The primary objective of this study was to assess whether metformin prevents or reverses BWG...